The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure

BACKGROUND: Sacubitril valsartan and valsartan are the first new drugs approved for angiotensin receptor neprilysin lysine inhibitors (ARNIs) in outpatients with chronic heart failure (CHF) and hypertension. Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Haiping, Li, Xiao, Zhao, Weifang, Jiang, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881145/
https://www.ncbi.nlm.nih.gov/pubmed/35222898
http://dx.doi.org/10.1155/2022/9494981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881145/
https://www.ncbi.nlm.nih.gov/pubmed/35222898
http://dx.doi.org/10.1155/2022/9494981

Ejemplares similares